natgillin/translations-raw huggingface dataset:
De signifikante fald i HbA1c observeret med 25 mg alogliptin og 30 mg pioglitazon og metformin var ensartede gennem behandlingsperioden på 52 uger sammenlignet med behandling med 45 mg pioglitazon og metformin (p<0,001 til alle tidspunkter).
The significant reductions in HbA1c observed with 25 mg alogliptin plus 30 mg pioglitazone and metformin were consistent over the entire 52-week treatment period compared to 45 mg pioglitazone and metformin (p<0.001 at all time points).
En samlet analyse af data fra 12 studier viste, at den samlede forekomst af hypoglykæmi var lavere hos patienter behandlet med 25 mg alogliptin end hos patienter behandlet med 12,5 mg alogliptin, aktiv kontrol eller placebo (henholdsvis 3,6 %, 4,6 %, 12,9 % og 6,2 %).
In a pooled analysis of the data from 12 studies, the overall incidence of any episode of hypoglycaemia was lower in patients treated with 25 mg alogliptin than in patients treated with 12.5 mg alogliptin, active control or placebo (3.6%, 4.6%, 12.9% and 6.2%, respectively).
Alogliptins farmakokinetik hos børn og unge under 18 år er ikke klarlagt.
The pharmacokinetics of alogliptin in children and adolescents <18 years old has not been established.
Vipdomet sikkerhed og virkning hos børn og unge under 18 år er ikke klarlagt.
The safety and efficacy of Vipdomet in children and adolescents <18 years old have not been established.
• Tegn på lavt blodsukker (hypoglykæmi), som kan opstå, hvis Vipdomet tages i kombination med insulin eller sulfonylurinstof (f.eks. glipizid, tolbutamid eller glibenclamid).
Common (may affect up to 1 in 10 people): - Symptoms of low blood sugar (hypoglycaemia) may occur when Vipdomet is taken in combination with insulin or sulphonylureas (e.g. glipizide, tolbutamide, glibenclamide).
Placebokontrolleret studie med kombinationsbehandling som supplement Alogliptin 25 mg én gang dagligt sammen med metformin (n = 203)
Add-on combination therapy placebo-controlled studies Alogliptin 25 mg once daily with metformin (n=203)
Det frarådes, at du tager Vipdomet, hvis du ammer, da indholdsstoffet metformin udskilles i modermælken.
Vipdomet is not recommended during breast-feeding since metformin passes into breast milk.
Lægemidlet skal også tages sammen med et måltid for at reducere de gastrointestinale bivirkninger ved metformin (se pkt.
It should also be taken with meals to reduce the gastrointestinal undesirable effects associated with metformin (see section 4.2).
På grund af indholdet af metformin må Vipdomet ikke anvendes til patienter med svært nedsat nyrefunktion eller terminal nyresygdom (se pkt.
Due to its metformin component, Vipdomet should not be used in patients with severe renal impairment, or end-stage renal disease requiring dialysis (see section 4.2).
Bioækvivalensstudier viser imidlertid, at Vipdomet, filmovertrukne tabletter er bioækvivalente med tilsvarende doser af alogliptin og metformin givet samtidigt som separate tabletter.
However, the results of bioequivalence studies have demonstrated that Vipdomet film-coated tablets are bioequivalent to the corresponding doses of alogliptin and metformin co-administered as separate tablets.
(-uendelig, -0,35)
(-infinity, -0.35)
Ændring i uge 52 (n = 382)
Change at Week 52 (n=382)
Patienter, der skifter fra separate alogliptin- og metformin-tabletter (som tostofbehandling eller som trestofbehandling sammen med insulin), skal tage den samme daglige dosis af både alogliptin og metformin.
For patients switching from separate tablets of alogliptin and metformin (as dual therapy or as part of triple therapy with insulin), both alogliptin and metformin should be dosed at the total daily dose already being taken; the individual dose of alogliptin should be halved as it will be taken twice daily whilst the dosing of metformin should remain unchanged.
INFORMATION I BRAILLESKRIFT Vipdomet 12,5 mg/850 mg
INFORMATION IN BRAILLE Vipdomet 12.5 mg/850 mg
• hvis du tager et andet lægemiddel mod diabetes, som indeholder et såkaldt sulfonylurinstof.
- if you are taking another medicine for diabetes that contains a “sulphonylurea”, you should not start taking Vipdomet.
Signifikant flere af de patienter, der fik 12,5 mg alogliptin og 1.000 mg metforminhydrochlorid to gange dagligt (59,5 %), nåede i uge 26 behandlingsmålet for HbA1c på < 7,0 % sammenlignet med dem, der fik 12,5 mg alogliptin givet alene to gange dagligt (20,2 %, p<0,001), og sammenlignet med dem, der fik 1.000 mg metforminhydrochlorid givet alene to gange dagligt (34,3 %, p<0,001).
Significantly more patients receiving 12.5 mg alogliptin and 1.000 mg metformin hydrochloride twice daily (59.5%) achieved target HbA1c levels of < 7.0% compared to those receiving either 12.5 mg alogliptin twice daily alone (20.2%, p<0.001) or 1,000 mg metformin hydrochloride twice daily alone (34.3%, p<0.001) at Week 26.
Vipdomets farmakokinetik hos børn og unge under 18 år er ikke klarlagt.
The pharmacokinetics of Vipdomet in children and adolescents <18 years old has not been established.
Lever- og galdeveje hepatitis meget sjælden uregelmæssige værdier set i leverfunktionstest meget sjælden leverdysfunktion herunder leversvigt ikke kendt
Liver function test abnormalities very rare hepatic dysfunction including hepatic failure not known
For patienter, der ikke opnår tilstrækkelig kontrol ved tostofbehandling med de maksimalt tolererede doser metformin og pioglitazon, skal dosis for pioglitazon fastholdes og Vipdomet skal administreres samtidigt; der skal gives 12,5 mg alogliptin to gange dagligt (25 mg i alt pr. dag) og metforminhydrochlorid i en dosis, der svarer til den, de allerede får (enten 850 mg eller 1.000 mg to gange dagligt).
For patients inadequately controlled on dual therapy with a maximal tolerated dose of metformin and pioglitazone, the dose of pioglitazone should be maintained, and Vipdomet administered concomitantly; alogliptin should be dosed at 12.5 mg twice daily (25 mg total daily dose) and metformin hydrochloride at a similar dose (either 850 mg or 1,000 mg twice daily) to that already being taken.
Ved fødeindtagelse bliver metforminabsorptionen en anelse forsinket og reduceret.
Food slightly delays and decreases the extent of the absorption of metformin.
I uge 52 svarede reduktionen i HbA1c med 25 mg alogliptin plus metformin (-0,76 %, tabel 3) til den, som blev opnået med glipizid (gennemsnitlig dosis = 5,2 mg) plus metforminhydrochloridbehandling (gennemsnitsdosis = 1.824 mg, -0,73 %).
At Week 52, the HbA1c reduction by 25 mg alogliptin plus metformin (-0.76%, Table 3) was similar to that produced by glipizide (mean dose = 5.2 mg) plus metformin hydrochloride therapy (mean dose = 1,824 mg, -0.73%).
I dyrestudier gennemført med alogliptin eller med metformin er der ikke observeret nogen indvirkninger på fertilitet (se pkt.
No adverse effects on fertility were observed in animal studies conducted with alogliptin or with metformin (see section 5.3).
Samtidig administration af 12,5 mg alogliptin og 1.000 mg metforminhydrochlorid to gange dagligt resulterede i statistisk signifikante forbedringer af HbA1c og fasteplasmaglucose fra baseline til uge 26 sammenlignet med både 12,5 mg alogliptin givet alene to gange dagligt og 1.000 mg metforminhydrochlorid givet alene to gange dagligt.
Co-administration of 12.5 mg alogliptin and 1,000 mg metformin hydrochloride twice daily resulted in statistically significant improvements from baseline in HbA1c and fasting plasma glucose at Week 26 when compared to either 12.5 mg alogliptin twice daily alone or 1,000 mg metformin hydrochloride twice daily alone.
Behandling med Vipdomet skal afbrydes forud for eller på tidspunktet for billeddiagnostiske procedurer og først genoptages mindst 48 timer herefter, forudsat at nyrefunktionen er blevet vurderet og fundet stabil, se pkt.
Vipdomet should be discontinued prior to or at the time of the imaging procedure and not restarted until at least 48 hours after, provided that renal function has been re-evaluated and found to be stable, see sections 4.2 and 4.5.
Behandling med Vipdomet skal afbrydes forud for eller på tidspunktet for en billeddiagnostisk procedure og først genoptages efter mindst 48 timer, forudsat at nyrefunktionen er blevet vurderet og fundet stabil, se pkt.
Vipdomet must be discontinued prior to or at the time of the imaging procedure and not restarted until at least 48 hours after, provided that renal function has been re-evaluated and found to be stable, see sections 4.2 and 4.4.
Flere patienter, der fik 25 mg alogliptin og metformin (48,5 %) nåede behandlingsmålet for HbA1c-niveau på ≤ 7,0 % sammenlignet med dem, der fik glipizid og metformin (42,8 %) (p=0,004).
More patients receiving 25 mg alogliptin and metformin (48.5%) achieved target HbA1c levels of ≤7.0% compared to those receiving glipizide and metformin (42.8%) (p=0.004).
Primært sammensat endepunkt [første hændelse af KV-død, ikkedødeligt MI og ikke-dødelig apopleksi] Kardiovaskulær død* Ikke-dødeligt myokardieinfarkt Ikke-dødelig apopleksi
Primary Composite Endpoint [First Event of CV Death, Nonfatal MI and Nonfatal Stroke]
INFORMATION I BRAILLESKRIFT Vipdomet 12,5 mg/1.000 mg
INFORMATION IN BRAILLE Vipdomet 12.5 mg/1000 mg
Patienter, der ikke opnår tilstrækkelig kontrol ved tostofbehandling sammen med insulin og den maksimalt tolererede dosis metformin, får via en dosis Vipdomet tilført 12,5 mg alogliptin to gange dagligt (25 mg i alt pr. dag) og en dosis metformin svarende til den, som de allerede får.
For patients inadequately controlled on dual combination therapy with insulin and the maximal tolerated dose of metformin, the dose of Vipdomet should provide alogliptin dosed at 12.5 mg twice daily (25 mg total daily dose) and a dose of metformin similar to the dose already being taken.
Der er indberettet enkelte tilfælde af hepatitis og uregelmæssige værdier er set i leverfunktionstest, som er forsvundet igen ved ophør med metformin.
Isolated cases of hepatitis or liver function test abnormalities resolving on discontinuation of metformin have been reported.
Tillægsbehandlingsstudier Alogliptin 25 mg én gang dagligt sammen med metformin versus et sulfonylurinstof + metformin
Add-on combination therapy studies Alogliptin 25 mg once daily with metformin vs a sulphonylurea + metformin
Administration af 25 mg alogliptin én gang dagligt som tillæg til 30 mg pioglitazon plus metforminbehandling (gennemsnitlig dosis = 1.867,9 mg) medførte forbedringer i HbA1c fra baseline til uge 52, der var både non-inferiøre og statistisk større end dem, der blev opnået ved administration af 45 mg pioglitazon og metforminbehandling gav (gennemsnitlig dosis = 1.847,6 mg, tabel 3).
The addition of 25 mg alogliptin once daily to 30 mg pioglitazone in combination with metformin hydrochloride therapy (mean dose = 1,867.9 mg) resulted in improvements from baseline in HbA1c at Week 52 that were both non-inferior and statistically superior to those produced by 45 mg pioglitazone in combination with metformin hydrochloride therapy (mean dose = 1,847.6 mg, Table 3).
Bioækvivalensstudier med raske forsøgspersoner viser, at Vipdomet, filmovertrukne-tabletter er bioækvivalente med tilsvarende doser af alogliptin og metformin givet samtidigt som separate tabletter.
The results of bioequivalence studies in healthy subjects demonstrated that Vipdomet film-coated tablets are bioequivalent to the corresponding doses of alogliptin and metformin co-administered as separate tablets.
• Stærke og vedvarende smerter i maven, som kan stråle ud i ryggen, samt kvalme og opkastning.
- Severe and persistent pain in the abdomen (stomach area) which might reach through to your back as well as nausea and vomiting, as it could be a sign of an inflamed pancreas (pancreatitis).
Nedsat leverfunktion Vipdomet må ikke anvendes til patienter med nedsat leverfunktion (se pkt.
Hepatic impairment Vipdomet should not be used in patients with hepatic impairment (see section 4.2).
Tegnene kan være udslæt, nældefeber, synke- eller åndedrætsbesvær, hævelse af læber, ansigt, svælg eller tunge og besvimelsesfornemmelse.
The symptoms may include: a rash, hives, swallowing or breathing problems, swelling of your lips, face, throat or tongue and feeling faint.
Sådan skal du tage Vipdomet
How to take Vipdomet
• hvis du er allergisk over for alogliptin, metformin eller et af de øvrige indholdsstoffer i dette lægemiddel (angivet i punkt 6).
Do not take Vipdomet: - if you are allergic to alogliptin, metformin or any of the other ingredients of this medicine (listed in section 6) - if you have had a serious allergic reaction to any other similar medicines that you take to control your blood sugar.
Tegnene kan være: rysten, svedtendens, angst, sløret syn, prikkende fornemmelse i læber, bleghed, humørsvingninger eller forvirring.
Symptoms may include: trembling, sweating, anxiety, blurred vision, tingling lips, paleness,
Endvidere var den gennemsnitlige ændring i fasteplasmaglucose fra baseline til uge 52 for 25 mg alogliptin plus metformin signifikant større end for glipizid plus metformin (p<0,001).
Mean change from baseline in fasting plasma glucose at Week 52 for 25 mg alogliptin and metformin was significantly greater than that for glipizide and metformin (p<0.001).
Vipdomet fås som filmovertrukne tabletter i styrkerne 12,5 mg/850 mg og 12,5 mg/1.000 mg.
For the different dose regimens Vipdomet is available in strengths of 12.5 mg/850 mg and 12.5 mg/1,000 mg film-coated tablets.
Signifikant flere af de patienter, der fik 25 mg alogliptin og 30 mg pioglitazon og metformin (33,2 %), nåede behandlingsmålet i uge 52 (p<0,001) for HbA1c på ≤ 7,0 % i forhold til de patienter, der fik 45 mg pioglitazon og metformin (21,3 %).
Significantly more patients receiving 25 mg alogliptin plus 30 mg pioglitazone and metformin (33.2%) achieved target HbA1c levels of ≤7.0% compared to those receiving 45 mg pioglitazone and metformin (21.3%) at Week 52 (p<0.001).
• hvis du for nyligt har haft et hjerteanfald eller har svære kredsløbsproblemer, herunder shock.
- if you have a severe infection or are seriously dehydrated (have lost a lot of water from your body) - if you recently had a heart attack or have severe circulatory problems including shock - if you have severe breathing difficulties - if you have liver disease - if you drink alcohol excessively (either every day or in large quantities only from time to time)
Tillæg af 25 mg alogliptin én gang dagligt til metforminbehandling (gennemsnitlig dosis = 1.847 mg) resulterede i statistisk signifikante forbedringer af HbA1c og fasteplasmaglucose fra baseline til uge 26 sammenlignet med tillæg af placebo (tabel 2).
The addition of 25 mg alogliptin once daily to metformin hydrochloride therapy (mean dose = 1,847 mg) resulted in statistically significant improvements from baseline in HbA1c and fasting plasma glucose at Week 26 when compared to the addition of placebo (Table 2).
ANGIVELSE AF AKTIVT STOF/AKTIVE STOFFER Hver tablet indeholder 12,5 mg alogliptin (som benzoat) og 1.000 mg metforminhydrochlorid.
STATEMENT OF ACTIVE SUBSTANCE(S) Each tablet contains 12.5 mg alogliptin (as benzoate) and 1,000 mg metformin hydrochloride.
• problemer med leveren (hepatitis eller unormale leverfunktionstest).
becoming breathless - Liver problems (hepatitis or liver function test abnormalities) - Erythema (redness of skin).
ANGIVELSE AF AKTIVT STOF/AKTIVE STOFFER Hver tablet indeholder 12,5 mg alogliptin (som benzoat) og 850 mg metforminhydrochlorid.
STATEMENT OF ACTIVE SUBSTANCE(S) Each tablet contains 12.5 mg alogliptin (as benzoate) and 850 mg metformin hydrochloride.
5.3) ved doser, som er ca. 5-20 gange højere (for henholdsvis metformin og alogliptin) end den humane eksponering ved den anbefalede dosis.
Studies in pregnant rats with alogliptin plus metformin as combination treatment have shown reproductive toxicity (see section 5.3) at approximately 5-20 times (for metformin and alogliptin respectively) the human exposure at the recommended dose.
LÆGEMIDLETS NAVN Vipdomet 12,5 mg/850 mg filmovertrukne tabletter Vipdomet 12,5 mg/1.000 mg filmovertrukne tabletter
NAME OF THE MEDICINAL PRODUCT Vipdomet 12.5 mg/850 mg film-coated tablets Vipdomet 12.5 mg/1,000 mg film-coated tablets
Dosisjustering er ikke nødvendig på grund af alder. Der bør dog udvises forsigtighed ved doseringen af alogliptin til ældre patienter, da de har forhøjet risiko for nedsat nyrefunktion.
However, dosing of alogliptin should be conservative in patients with advanced age due to the potential for decreased renal function in this population
Den gennemsnitlige ændring i fasteplasmaglucose fra baseline til uge 52 ved administration af 25 mg alogliptin plus 30 mg pioglitazon plus metformin var desuden signifikant større end den gennemsnitlige ændring, der blev registreret ved administration af 45 mg pioglitazon plus metformin (p<0,001).
In addition, mean change from baseline in FPG at Week 52 for 25 mg alogliptin plus 30 mg pioglitazone and metformin was significantly greater than that for 45 mg pioglitazone and metformin (p<0.001).
Patienterne skal informeres om at stoppe med at tage Vipdomet og øjeblikkeligt søge lægehjælp ved symptomer, der kan give mistanke om laktatacidose.
In case of suspected symptoms, the patient should stop taking Vipdomet and seek immediate medical attention.
Alogliptin som tillæg til metformin sammen med et thiazolidindion Tillæg af 25 mg alogliptin én gang dagligt til pioglitazonbehandling (gennemsnitlig dosis = 35,0 mg, med eller uden metformin eller sulfonylurinstof) resulterede i statistisk signifikante forbedringer af HbA1c og fasteplasmaglucose i forhold til baseline i uge 26 sammenlignet med tillæg af placebo (tabel 2).
Alogliptin as add-on therapy to metformin with a thiazolidinedione The addition of 25 mg alogliptin once daily to pioglitazone therapy (mean dose = 35.0 mg, with or without metformin or a sulphonylurea) resulted in statistically significant improvements from baseline in HbA1c and fasting plasma glucose at Week 26 when compared to the addition of placebo (Table 2).
Alogliptin som tillæg til metformin sammen med insulin Tillæg af 25 mg alogliptin én gang dagligt til insulinbehandling (gennemsnitlig dosis = 56,5 IE, med eller uden metformin) resulterede i statistisk signifikante forbedringer af HbA1c og fasteplasmaglucose fra baseline til uge 26 sammenlignet med tillæg af placebo (tabel 2).
Alogliptin as add-on therapy to metformin with insulin The addition of 25 mg alogliptin once daily to insulin therapy (mean dose = 56.5 IU, with or without metformin) resulted in statistically significant improvements from baseline in HbA1c and FPG at Week 26 when compared to the addition of placebo (Table 2).
Det skal du vide, før du begynder at tage Vipdomet Sådan skal du tage Vipdomet Bivirkninger
What Vipdomet is and what it is used for What you need to know before you take Vipdomet How to take Vipdomet
Flere af de patienter, der fik 25 mg alogliptin (7,8 %), nåede behandlingsmålet i uge 26 for HbA1c på ≤ 7,0 %, sammenlignet med de placebobehandlede patienter (0,8 %).
More patients receiving 25 mg alogliptin (7.8%) achieved target HbA1c levels of ≤7.0% compared to those receiving placebo (0.8%) at Week 26.
Signifikant flere patienter, der fik 25 mg alogliptin (44,4 %), nåede i uge 26 behandlingsmålet for HbA1c på ≤ 7,0 % sammenlignet med de placebobehandlede patienter (18,3 %) (p<0,001).
Significantly more patients receiving 25 mg alogliptin (44.4%) achieved target HbA1c levels of ≤7.0% compared to those receiving placebo (18.3%) at Week 26 (p<0.001).
- Hver 12,5 mg/850 mg filmovertrukken tablet indeholder alogliptinbenzoat svarende til 12,5 mg alogliptin og 850 mg metforminhydrochlorid.
Each 12.5 mg/850 mg film-coated tablet contains alogliptin benzoate equivalent to 12.5 mg alogliptin and 850 mg metformin hydrochloride.
- Hver 12,5 mg/1.000 mg filmovertrukken tablet indeholder alogliptinbenzoat svarende til 12,5 mg alogliptin og 1.000 mg metforminhydrochlorid.
Each 12.5 mg/1,000 mg film-coated tablet contains alogliptin benzoate equivalent to 12.5 mg alogliptin and 1,000 mg metformin hydrochloride.
svaghedsfornemmelse og stakåndethed.
mood change or feeling confused.
- Vipdomet 12,5 mg/1.000 mg filmovertrukne tabletter (tabletter) er svagt gule, aflange (ca. 22,3 x 10,7 mm), bikonvekse filmovertrukne tabletter, der er præget med "12.5/1000" på den ene side og "322M" på den anden side.
- Vipdomet 12.5 mg/1,000 mg film-coated tablets (tablets) are pale yellow, oblong (approximately 22.3 mm long by 10.7 mm wide), biconvex, film-coated tablets with “12.5/1000” debossed on one side and “322M” debossed on the other side.
Signifikant flere af de patienter, der fik 25 mg alogliptin (49,2 %), nåede behandlingsmålet i uge 26 (p=0,004) for HbA1c på ≤ 7,0 %, i forhold til de placebobehandlede patienter (34,0 %).
Significantly more patients receiving 25 mg alogliptin (49.2%) achieved target HbA1c levels of ≤7.0% compared to those receiving placebo (34.0%) at Week 26 (p=0.004).
Udseende og pakningsstørrelser - Vipdomet 12,5 mg/850 mg filmovertrukne tabletter (tabletter) er lysegule, aflange (ca. 21,0 x 10,1 mm), bikonvekse filmovertrukne tabletter, der er præget med "12.5/850" på den ene side og "322M" på den anden side.
What Vipdomet looks like and contents of the pack - Vipdomet 12.5 mg/850 mg film-coated tablets (tablets) are light yellow, oblong (approximately 21.0 mm long by 10.1 mm wide), biconvex, film-coated tablets with “12.5/850” debossed on one side and “322M” debossed on the other side.
MARKEDSFØRINGSTILLADELSESNUMMER (-NUMRE) EU/1/13/843/026 196 (2x98) filmovertrukne tabletter (multipakning)
MARKETING AUTHORISATION NUMBER(S) EU/1/13/843/026 196 (2x98) film-coated tablets (multipack)
• nedsat B12-vitaminniveau eller anæmi.
Very rare: - Decreased vitamin B12 levels or anaemia; symptoms include tiredness, lethargy, feeling faint,
MARKEDSFØRINGSTILLADELSESNUMMER (-NUMRE) EU/1/13/843/025 196 (2x98) filmovertrukne tabletter (multipakning)
MARKETING AUTHORISATION NUMBER(S) EU/1/13/843/025 196 (2x98) film-coated tablets (multipack)
• leverproblemer, der viser sig som kvalme, opkastning, mavesmerter, usædvanlig eller uforklarlig træthed, manglende appetit, mørkfarvet urin eller gulfarvning af huden eller det hvide i øjnene.
loss of appetite, dark urine or yellowing of your skin or the whites of your eyes.
Gennem-snitlig ændring i HbA1c fra baseline (%)† (SE)
Mean change from baseline in HbA1c (%)† (SE)
MARKEDSFØRINGSTILLADELSESNUMMER (-NUMRE) EU/1/13/843/025 2x98 filmovertrukne tabletter
MARKETING AUTHORISATION NUMBER(S) EU/1/13/843/025 2x98 film-coated tablets
Metabolisme og ernæring laktatacidose meget sjælden
Hepatobiliary disorders hepatitis very rare
MARKEDSFØRINGSTILLADELSESNUMMER (-NUMRE) EU/1/13/843/026 2x98 filmovertrukne tabletter
MARKETING AUTHORISATION NUMBER(S) EU/1/13/843/026 2x98 film-coated tablets
Indlægsseddel: Information til patienten Vipdomet 12,5 mg/850 mg filmovertrukne tabletter Vipdomet 12,5 mg/1.000 mg filmovertrukne tabletter alogliptin/metforminhydrochlorid
Vipdomet 12.5 mg/850 mg film-coated tablets Vipdomet 12.5 mg/1000 mg film-coated tablets alogliptin/metformin hydrochloride
LÆGEMIDLETS NAVN Vipdomet 12,5 mg/1.000 mg tabletter alogliptin/metforminhydrochlorid
NAME OF THE MEDICINAL PRODUCT Vipdomet 12.5 mg/1,000 mg tablets alogliptin/metformin hydrochloride
LÆGEMIDLETS NAVN Vipdomet 12,5 mg/850 mg tabletter alogliptin/metforminhydrochlorid
NAME OF THE MEDICINAL PRODUCT Vipdomet 12.5 mg/850 mg tablets alogliptin/metformin hydrochloride
Hvis du har taget for meget Vipdomet
If you take more Vipdomet than you should
Farmakoterapeutisk klassifikation: antidiabetika; komb.
Pharmacotherapeutic group: Drugs used in diabetes; combinations of oral blood glucose lowering drugs.
LÆGEMIDLETS NAVN Vipdomet 12,5 mg/1.000 mg filmovertrukne tabletter alogliptin/metforminhydrochlorid
NAME OF THE MEDICINAL PRODUCT Vipdomet 12.5 mg/1,000 mg film-coated tablets alogliptin/metformin hydrochloride
LÆGEMIDLETS NAVN Vipdomet 12,5 mg/850 mg filmovertrukne tabletter alogliptin/metforminhydrochlorid
NAME OF THE MEDICINAL PRODUCT Vipdomet 12.5 mg/850 mg film-coated tablets alogliptin/metformin hydrochloride
Behandlingskorrigeret ændring i HbA1c (%)† (en-sidet
Treatment-corrected change from baseline in HbA1c (%)†